New Hope for Lung Cancer Patients with Drug Resistance
Israeli Researchers Explore a Promising Combination Therapy
Lung cancer is responsible for approximately one-fifth of all cancer deaths worldwide, according to the World Health Organization. Typically, new-generation drugs are used to treat specific subtypes of lung cancer by targeting their respective genetic mutations. Initially, these therapies are effective in many patients. However, within about one year, the patients tend to develop resistance to the drugs. In response, researchers at the Weizmann Institute of Science have collaborated with physicians from Sheba Medical Center to conduct a study in mice. They applied a new combination of existing drugs to help suppress potential resistance to the cancer treatment. The results of the study were published recently in the journal Clinical Cancer Research.